StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
AZTRAzitra, Inc.
stockpulse.co.kr
NYSE
$0.0715▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.2MShares out 16.2M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

14
  • 2d agoAfter-hours26.10.23 05:15
    8-KKey event#●●●

    Azitra, Inc.

    Azitra, Inc. will effect a 1-for-10 reverse stock split effective at 12:01 a.m. on October 26, 2026. Following this action, every 10 outstanding shares will be combined into one share, and the common stock is expected to begin trading on a split-adjusted basis at market open on October 26, 2026.…more

    $0.0715+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.1Pre-market26.10.01 21:10
    8-KKey event

    Azitra, Inc.

    Azitra has successfully completed Cohort 1 of its Phase 1/2 clinical trial for ATR-04, a treatment for EGFR inhibitor-associated skin rash, and received clearance from the safety review committee to proceed to Cohort 2. The company will now begin enrollment and dosing for approximately 24 patients in the second cohort, marking a significant milestone in addressing this debilitating side effect for cancer patients.…more

    $0.0715+0.00%vs prev close
    View filingShare
  • 9.28After-hours26.09.29 05:50
    8-KKey event

    Azitra, Inc.

    Azitra, Inc. entered into a sales agreement on September 28, 2026, with A.G.P./Alliance Global Partners to issue and sell common stock through an at-the-market (ATM) offering for up to $3,503,232. The company intends to use the net proceeds for working capital and general corporate purposes, with shares issued under an existing effective Form S-3 registration statement.…more

    $0.0715+0.00%vs prev close
    View filingShare

13 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.28After-hours26.09.29 05:50
    Bullish#●●●#●●●#●●●

    Azitra Enters Sales Agreement For Up To $3.5M Common Stock Offering

    Azitra has entered into a sales agreement with A.G.P. to offer up to $3.5 million in common stock. The potential for share dilution following this offering may impact existing shareholders.…more

    $0.0715+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 8.21Pre-market26.08.21 21:02

    ●●●●●●●● ●●●●● ●●●●●●

    Azitra has received notification from the NYSE American exchange confirming it has regained compliance with all continued listing standards. This development resolves the risk of delisting and allows the company to maintain its listing status.…more

    $0.0715+0.00%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →